Inventor · disambiguated record
Hartmut Koeppen
Also filed as: KOEPPEN HARTMUT
16 granted patents·36 pending applications·555 citations·filing 2000–2025
94Inventor score
Top patents by PatentIndex Score
52 records- 0196US6824780B1Anti-tumor antibody compositions and methods of useGENENTECH INC·Filed 2000·Granted Nov 30, 2004·264 cites·9 claims
- 0294US7749504B2Anti-TAT188 antibodiesGENENTECH INC·Filed 2007·Granted Jul 6, 2010·16 cites·23 claims
- 0394US6689744B2Notch receptor agonists and usesGENENTECH INC·Filed 2001·Granted Feb 10, 2004·157 cites·9 claims
- 0493US7390882B2Compositions and methods for the diagnosis and treatment of tumorGENENTECH INC·Filed 2005·Granted Jun 24, 2008·11 cites·3 claims
- 0592US10689445B2Anti-PD-L1 antibodies and diagnostic uses thereofVENTANA MED SYST INC·Filed 2017·Granted Jun 23, 2020·6 cites·28 claims
- 0690US7858330B2Compositions and methods for the treatment of tumor of hematopoietic originGENENTECH INC·Filed 2006·Granted Dec 28, 2010·15 cites·20 claims
- 0790US7803915B2Antibody compositions for the diagnosis and treatment of tumorGENENTECH INC·Filed 2004·Granted Sep 28, 2010·34 cites·26 claims
- 0889US7888478B2Compositions and methods for the treatment of tumor of hematopoietic originGENENTECH INC·Filed 2005·Granted Feb 15, 2011·15 cites·92 claims
- 0988US8278042B2Compositions and methods for the diagnosis and treatment of tumorCAIRNS BELINDA·Filed 2010·Granted Oct 2, 2012·6 cites·3 claims
- 1088US7435416B2Anti-tumor antibody compositions and methods of useGENENTECH INC·Filed 2004·Granted Oct 14, 2008·18 cites·7 claims
- 1188US2025093359A1Biomarkers and methods of treating pd-1 and pd-l1 related conditionsGENENTECH INC·Filed 2024·Application pending·0 cites
- 1288US2025052759A1Biomarkers and methods of treating pd-1 and pd-l1 related conditionsGENENTECH INC·Filed 2024·Application pending·0 cites
- 1386US2024248092A1Biomarkers and methods of treating pd-1 and pd-l1 related conditionsGENENTECH INC·Filed 2024·Application pending·0 cites
- 1485US8388973B2Compositions and methods for the treatment of tumor of hematopoietic originCHANG WESLEY·Filed 2010·Granted Mar 5, 2013·7 cites·58 claims
- 1579US10240207B2Cancer treatment with c-met antagonists and correlation of the latter with HGF expressionGENENTECH INC·Filed 2016·Granted Mar 26, 2019·6 cites·25 claims
- 1678US2023159641A1Anti-pd-l1 antibodies and diagnostic uses thereofVENTANA MED SYST INC·Filed 2022·Application pending·0 cites
- 1778US2009324592A1Compositions and methods for the diagnosis and treatment of tumorCAIMS BELINDA·Filed 2009·Application pending·0 cites
- 1875US2009136928A1Compositions and Methods for the Diagnosis and Treatment of TumorGENENTECH INC·Filed 2007·Application pending·0 cites
- 1975US2022146517A1Biomarkers and methods of treating pd-1 and pd-l1 related conditionsGENENTECH INC·Filed 2021·Application pending·0 cites
- 2074US2009081660A1Compositions and methods for the diagnosis and treatment of tumorCAIRNS BELINDA·Filed 2008·Application pending·0 cites
- 2173US2025164494A1Biomarkers and methods of treating pd-1 and pd-l1 related conditionsGENENTECH INC·Filed 2025·Application pending·0 cites
- 2273US2020041520A1Biomarkers and methods of treating pd-1 and pd-l1 related conditionsGENENTECH INC·Filed 2019·Application pending·0 cites
- 2373US2021140967A1Biomarkers and methods of treating pd-1 and pd-l1 related conditionsGENENTECH INC·Filed 2021·Application pending·0 cites
- 2471US11530269B2Anti-PD-L1 antibodies and diagnostic uses thereofVENTANA MED SYST INC·Filed 2020·Granted Dec 20, 2022·0 cites·20 claims
- 2571US2019195882A1Biomarkers and methods of treating pd-1 and pd-l1 related conditionsGENENTECH INC·Filed 2019·Application pending·0 cites
- 2670US2020333348A1Biomarkers and methods of treating pd-1 and pd-l1 related conditionsGENENTECH INC·Filed 2020·Application pending·0 cites
- 2770US2009324490A1Compositions and methods for the diagnosis and treatment of tumorCAIMS BELINDA·Filed 2009·Application pending·0 cites
- 2870US2009246129A1Compositions and methods for the diagnosis and treatment of tumorCAIMS BELINDA·Filed 2009·Application pending·0 cites
- 2969US2018313845A1Biomarkers and methods of treating pd-1 and pd-l1 related conditionsGENENTECH INC·Filed 2018·Application pending·0 cites
- 3066US8728480B2Methods for the treatment of tumors expressing TAT123 or naturally occurring variants thereofCAIRNS BELINDA·Filed 2011·Granted May 20, 2014·0 cites·25 claims
- 3166US2007048326A1Compositions and Methods for the Diagnosis and Treatment of TumorGENENTECH INC·Filed 2006·Application pending·0 cites
- 3265US2008227106A1Compositions and methods for the diagnosis and treatment of tumorCAIRNS BELINDA·Filed 2008·Application pending·0 cites
- 3363US2017052188A1Biomarkers and methods of treating pd-1 and pd-l1 related conditionsGENENTECH INC·Filed 2016·Application pending·0 cites
- 3463US2009297531A1Compositions and methods for the diagnosis and treatment of tumorGENENTECH INC·Filed 2009·Application pending·0 cites
- 3562US2015071910A1Biomarkers and methods of treating pd-1 and pd-l1 related conditionsGENENTECH INC·Filed 2014·Application pending·0 cites
- 3659US2025046063A1Cell classification using center emphasis of a feature mapGENENTECH INC·Filed 2024·Application pending·0 cites
- 3757US2024346804A1Pipelines for tumor immunophenotypingGENENTECH INC·Filed 2024·Application pending·0 cites
- 3855US2024046473A1Transformation of histochemically stained images into synthetic immunohistochemistry (ihc) imagesVENTANA MED SYST INC·Filed 2023·Application pending·0 cites
- 3955US2024104948A1Tumor immunophenotyping based on spatial distribution analysisGENENTECH INC·Filed 2023·Application pending·0 cites
- 4055US2005107595A1Compositions and methods for the diagnosis and treatment of tumorGENENTECH INC·Filed 2004·Application pending·0 cites
- 4154US2008008705A1Cancer prognostic diagnostic and treatment methodsGENENTECH INC·Filed 2007·Application pending·0 cites
- 4254US2005226869A1Compositions and methods for the treatment of tumor of hematopoietic originGENENTECH INC·Filed 2004·Application pending·0 cites
- 4352US11299544B2Biomarkers and methods of treating PD-1 and PD-L1 related conditionsGENENTECH INC·Filed 2015·Granted Apr 12, 2022·0 cites·26 claims
- 4452US2015125452A1Combination treatments comprising c-met antagonists and b-raf antagonistsGENENTECH INC·Filed 2014·Application pending·0 cites
- 4551US8993249B2Anti-neuropilin antibodies and methods of useGENENTECH INC·Filed 2013·Granted Mar 31, 2015·0 cites·8 claims
- 4650US2010303834A1Compositions and methods for the diagnosis and treatment of tumorCAIRNS BELINDA·Filed 2010·Application pending·0 cites
- 4750US2009324595A1Cancer prognostic diagnostic and treatment methodsGENENTECH INC·Filed 2009·Application pending·0 cites
- 4849US2007117124A1Achaete-Scute Like-2 Polypeptides and Encoding Nucleic Acids and Methods for the Diagnosis and Treatment of TumorGENENTECH INC·Filed 2006·Application pending·0 cites
- 4948US2016009805A1Anti-pd-l1 antibodies and diagnostic uses thereofGENENTECH INC·Filed 2015·Application pending·0 cites
- 5048US2013078252A1Combination treatments comprising c-met antagonists and b-raf antagonistsGENENTECH INC·Filed 2012·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Hartmut Koeppen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →